Client-Sponsored Imaging Trials
Neurodegenerative and Neuropsychiatric Disorders
Phase 1 to Phase 4Active
Key Facts
Indication
Neurodegenerative and Neuropsychiatric Disorders
Phase
Phase 1 to Phase 4
Status
Active
Company
About XingImaging
XingImaging, founded in 2018 and based in Cambridge, Massachusetts, with a major operational facility in New Haven, Connecticut, is a specialized neuroimaging services provider. The company leverages scintigraphic imaging (e.g., PET, SPECT) and radiopharmaceutical expertise to support biopharma clients in developing and validating biomarkers for central nervous system disorders. Its integrated model spans radioligand manufacturing, clinical trial design, and multi-site imaging coordination, positioning it as a critical partner in the translational neuroscience space. As a subsidiary of MITRO, it benefits from corporate backing while operating with a focused team of over 40 staff.
View full company profile